BioMérieux submitted a rapid multiplex PCR vaginitis panel to the FDA for dual 510(k) clearance and CLIA waiver. The BioFire SpotFire Vaginitis Panel is designed to return results within 20 minutes at the point of care, covering multiple bacterial, yeast, and Trichomonas targets from a single swab. The filing supports BioMérieux’s expansion into women’s and sexual health diagnostics by enabling clinicians to diagnose and guide targeted treatment during the same visit. For the diagnostics market, rapid syndromic panels can reduce diagnostic delays and may influence prescribing patterns where empiric therapy has traditionally driven costs and variability.